Evidence map›Paper›PMID 41140753›Full record

ArticleGastro hep advances2026

Fecal

Ayaka Takaori, Tsukasa Ikeura, Daisuke Hashimoto, Motonobu Maruo, Masatoshi Ikeda, Takashi Ito, Koh Nakamaru, Masataka Masuda, Shinji Nakayama, Hidetaka Miyazaki and 9 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Gastro hep advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Ayaka TakaoriThird Department of Internal Medicine, Kansai Medical University, Osaka, Japan.
Tsukasa IkeuraThird Department of Internal Medicine, Kansai Medical University, Osaka, Japan.
Daisuke HashimotoDepartment of Pancreatobiliary Surgery, Kansai Medical University, Osaka, Japan.
Motonobu MaruoThird Department of Internal Medicine, Kansai Medical University, Osaka, Japan.
Masatoshi IkedaThird Department of Internal Medicine, Kansai Medical University, Osaka, Japan.
Takashi ItoThird Department of Internal Medicine, Kansai Medical University, Osaka, Japan.
Koh NakamaruThird Department of Internal Medicine, Kansai Medical University, Osaka, Japan.
Masataka MasudaThird Department of Internal Medicine, Kansai Medical University, Osaka, Japan.
Shinji NakayamaThird Department of Internal Medicine, Kansai Medical University, Osaka, Japan.
Hidetaka MiyazakiDepartment of Pancreatobiliary Surgery, Kansai Medical University, Osaka, Japan.
Kazuki MatsumuraDepartment of Pancreatobiliary Surgery, Kansai Medical University, Osaka, Japan.
So YamakiDepartment of Pancreatobiliary Surgery, Kansai Medical University, Osaka, Japan.
Tomoyo YasudaDepartment of Clinical Oncology, Kansai Medical University, Osaka, Japan.
Masashi KanaiDepartment of Clinical Oncology, Kansai Medical University, Osaka, Japan.
Shohei AkagawaDepartment of Pediatrics, Kansai Medical University, Osaka, Japan.
Shoji TsujiDepartment of Pediatrics, Kansai Medical University, Osaka, Japan.
Koichiro HigasaDepartment of Genome Analysis, Institute of Biomedical Science, Kansai Medical University, Osaka, Japan.
Sohei SatoiDepartment of Pancreatobiliary Surgery, Kansai Medical University, Osaka, Japan.
Makoto NaganumaThird Department of Internal Medicine, Kansai Medical University, Osaka, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background and Aims: To date, neoadjuvant chemotherapy (NAC) is a well-accepted therapeutic strategy for patients with resectable (R) and borderline resectable (BR) pancreatic ductal adenocarcinoma (PDAC). We previously reported that the relative abundance of Methods: In this prospective observational study, we analyzed 42 patients with R/BR-PDAC who underwent pancreatic resection following NAC with gemcitabine plus S-1 between 2020 and 2022 at Kansai Medical University Hospital. Stool samples were collected at PDAC diagnosis for microbiota analysis using 16S RNA gene sequences. In 19 genera accounting for ≥ 1% in relative abundance, the relationship between the microbiota profile and recurrence-free survival (RFS) and overall survival was examined using the Kaplan-Meier method and the Cox proportional hazards model. Results: The median postoperative observation period was 24 months. During the observation period, 23 patients (55%) experienced recurrence, and 10 patients (24%) died of PDAC. RFS was significantly favorable in patients in the high- Conclusion: The relative abundance of

Indexed as

BifidobacteriumGut MicrobiotaNeoadjuvant TherapyPancreatic Ductal Adenocarcinoma

Identifiers

PMID41140753
PMCPMC12546966

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.